Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modeled Dose Exposure of Sublingual Buprenorphine in Neonatal Opioid Abstinence Syndrome
NCT03608696Phase 2Completed
- Sponsor
- Thomas Jefferson University
- Start
- Aug 2018
- Primary completion
- Jul 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine in neonatal abstinence syndrome (NAS), sponsored by Thomas Jefferson University. Started Aug 2018; status: completed.
02
Drugs
buprenorphine
03
Conditions
neonatal abstinence syndrome (NAS)
Beyond the preview
Go deeper on NCT03608696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608696.